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1005-42 Recanalization of Long Superficial Femoral Artery 
Occlusions by a Transpopliteal Approach: Acute and 
12- Month Results
Malte Schroeder, Martin Möckel, Rainer Dietz, Giancarlo Biamino, Dierk Scheinert, 
Charité, Campus Virchow-Klinikum, Berlin, Germany, University of Leipzig-Heart Center, 
Leipzig, Germany
Objective: Although crossover recanalization of chronic superficial femoral artery (SFA)
has shown higher technical success rates than antegrade recanalization, in long chronic
SFA occlusions there is still a considerable technical failure rate due to inability to cross
the occlusion. 
Methods: We analyzed the acute and 12 month results of 103 patients who underwent
transpopliteal recanalization of long chronic SFA occlusions (mean length 14.8 cm). In 82
patients the popliteal approach was used as a salvage technique after failure to pass the
occlusion using an antgrade way due to subintimal passage. In the remaining 21 cases
the transpopliteal route was used as the primary approach to cross flush occlusions of
the SFA without patent proximal stump of the vessel. Puncture of the popliteal artery was
performed using fluorescopic control and road mapping after contrast injection through
an ipsilateral or contralateral F4 femoral access. In all cases the distal third of the SFA as
well as the popliteal artery were patent allowing placement of a 6 French introducer
sheath. Retrograde recanalization of the SFA occlusion was performed using hydrophilic
guide wires and Excimer laser assistance followed by adjunctive balloon angioplasty
(diameter 5-6 mm).
Results: A technical successful recanalization could be achieved in 89 of 103 cases
(86.4%). There were no major procedure related adverse events. Puncture site complica-
tions occured in 11 cases (10.7%). There were 3 false aneurysms (2.9%), 6 hematomas
(5.8%) and 2 cases of thrombotic occlusion of the popliteal artery / tibioperoneal trunk
(1.9%). In both cases we were able to mechanically recanalize the thrombotic occlusion.
Primary and secondary patency rates after 12 months as assessed by colour-coded
ultrasound were 54.4% and 73.8%, respectively.
Conclusion: The transpopliteal approach is an alternative effective technique to recana-
lize long SFA occlusions, which could not be crossed by standard techniques.
1005-43 The Foundation for Advanced Medical Education Renal 
and Iliac Artery Stent Training Program
David R. Holmes, Jr., Robert D. Fox, Carl Tommaso, Patricia K. Hodgson, Richard Green, 
Krishna Rocha-Singh, Kenneth Rosenfield, Mayo Clinic, Rochester, MN, Massachusetts 
General Hospital, Boston, MA
Background: Cardiovascular medicine continues to evolve rapidly as new approaches
and new technology are explored, developed, and incorporated into practice.Physicians,
particularly cardiologists, are expected to practice in the most effective manner by devel-
oping and disseminating new knowledge and new skills. To assess the effectiveness of
introducing new procedures to physicians already in practice, a group of interventional
cardiologists and vascular surgeons undertook an initiative to teach their peers to stent
renal and iliac arteries.
Methods: A comprehensive program was devised, including a didactic portion (via dis-
tance learning), an animal practicum, a simulation, and a preceptor/preceptee segment,
followed by an assessment by the participants. The program ascribed to the guidelines of
the American College of Cardiology for procedural training.
Results: Six preceptors and 25 preceptees undertook and later evaluated the program.
Preceptors were more critical of the overall initiative than preceptees, and surgeons were
more critical than cardiologists. Preceptors rated the skills of the cardiologists higher than
those of the surgeons. Preceptees gave the most enthusiastic feedback about the animal
practicum and provided helpful suggestions to improve the technical aspects of the simu-
lation.
Conclusion: Training physicians with different skill sets and cognitive processes is chal-
lenging, but overcoming the challenges is vital to assure that cardiovascular medicine
continues to move forward by incorporating new procedures that will improve patient
care.
1005-44 Vascular Brachytherapy With 192Iridium After 
Femoropopliteal Stenting in High-Risk Patients: Results 
From the Vienna-5 Trial
Roswitha M. Wolfram, Alexandra C. Budinsky, Boris Pokrajac, Schila Sabeti, Andrea 
Bartok, Richard Poetter, Erich Minar, University of Vienna, General Hospital Vienna, 
Vienna, Austria, Vienna, Austria, University of Vienna, General Hospital Vienna, Vienna, 
Austria
BACKGROUND: To evaluate the efficacy of endovascular brachytherapy (EBT) for the
prevention of restenosis after femoropopliteal stenting in high-risk patients. 
MATERIALS AND METHODS: A total of 88 patients with femoropopliteal lesions (mean
treatment length 16.8 ± 7.3 cm) were included into the trial. Patients underwent PTA and
stent implantation and were randomized in a double blinded fashion to receive either
gamma-EBT with an 192Iridium source or treatment with non-radioactive seeds. A dose of
14 Gy was prescribed at 2mm into the arterial wall (target depth = vessel radius + 2mm).
The primary endpoint was angiographic binary restenosis >50% at 6 months.
RESULTS: Revascularization and EBT were successfully accomplished in all patients.
The overall 6-month recurrence rate was 34.8% in the Stent- vs. 33.3% in the Stent plus
EBT group, (p=0.89). Nine (10.2%) patients developed early re-occlusion of the stented
segment (2 patients [4.3%] in the Stent- and 7 [16.7%] in the Stent + EBT group), among
those 3 patients in the EBT group within the first 24 hours after intervention. Late throm-
botic occlusion (LTO >30 days) was observed in 3 patients (7.1%) in the Stent plus EBT
group.
CONCLUSION: ETB does not improve 6-months patency after femoropopliteal stenting
in high risk patients, due to a high incidence of early and late thrombotic occlusion.
1005-45 Dose Response of Sirolimus-Eluting SMARTTM Stents in 
Porcine Iliac Arteries and Relationship to Arterial 
Tissue Sirolimus Levels
Michael A. Lauer, Jennifer J. DeVries, Patricia A. Turck, Raviprasad G. Subraya, Scott D. 
Haller, Clark Williard, Fermin O. Tio, John F. Dooley, Gregory A. Kopia, Borgess 
Research Institute, Kalamazoo, MI, Cordis Corporation, Warren, NJ
Background: The dose-response of peripheral arteries to sirolimus delivered from siroli-
mus-eluting stents has not been established. This study was performed to evaluate sev-
eral doses of sirolimus-eluting SMART stents and to correlate the vascular response to
tissue sirolimus levels. Methods: To assess efficacy, 8x40 mm SMART stents coated
with 50, 150, 500 & 1500µg/stent sirolimus or control metal or polymer-coated SMART
stents were implanted in the iliac arteries of 36 Yucatan miniswine. After a 30, 90 or 180
day recovery period, the iliac arteries were removed and prepared for histomorphometric
analysis. All doses were studied at 30 days but only the 500µg and 1500 µg/stent doses
were studied at 90 and 180 days. Arterial sirolimus was determined by implanting the
same four doses of drug eluting stents in the iliac arteries of an additional 45 miniswine
and removing the arteries after either 1, 3, 8 and 30 days; the 500 & 1500µg/stent doses
were continued for 90 days. Results: At 30 days, significant (p<0.05) reductions in neoin-
timal area were noted in the 150µg, 500µg and 1500µg/stent groups but not in the 50µg/
stent group (see Table). Peak tissue levels ranged from 0.6 to 68 ng/mg. However reduc-
tion in neointimal area was not observed with peak tissue levels below 1 ng/mg. Conclu-
sion: This dose-response revealed safety at all sirolimus doses and maximum benefit at
the 500µg dose. The lack of efficacy at 50µg establishes for the first time apparent mini-
mal tissue levels needed for pharmacological activity.
1005-46 Percutaneous Peripheral Intervention Is Associated 
With Sustained Improvement in Health-Related Quality 
of Life
Roberto A. Corpus, Jr., Gregory G. Pellizzon, John A. House, Willian C. Daniels, Steven 
B. Laster, Steven P. Marso, Mid America Heart Institute, Kansas City, MO
Background: There is a paucity of data substantiating benefit among patients undergo-
ing peripheral percutaneous intervention (PPI). The Peripheral Arterial Questionnaire
(PAQ) is a recently developed and validated 20-item self-administered Likert-style instru-
ment that assess functional and quality of life (QOL) limitations specifically due to periph-
eral arterial disease (PAD).
Methods: QOL assessments utilizing the PAQ were performed on 216 consecutive
patients undergoing lower extremity PPI for treatment of claudication prior to and 1,3,6,
and 12 months after PPI. 
Results: Of the 216 patients undergoing PPI, 130 (63%) were male, 79 (38%) had diabe-
tes, 129 (64%) had dyslipidemia, 134 (67%) had hypertension, 96 (46%) were current
smokers, and the mean age was 68 + 12 years. Angiographically, 58(28%) of patients
had bilateral disease, 104 (45%) had multilevel disease, and 46 (22%) had total occlu-
sions. Following PPI, there was a significant and sustained improvement in health related
QOL (p<0.001 for trend) [fig 1]. Variability in the magnitude of benefit 1 month following
PPI was observed (inset).
Conclusions: These data suggest that PPI for the treatment of lifestyle-limiting claudica-
tion is effective and associated with a significant and sustained improvement in QOL.
Further study is needed to understand the patient and procedural characteristics associ-
ated with the greatest benefit from PPI.
Dose Response Efficacy at Day 30 and Arterial Tissue Sirolimus Levels
Stent/
Dose
Initimal 
Area 
(mm2)
Intima/ 
Media 
Ratio
% Area 
Occlusion
Initimal 
Thickness 
(µm)
Tissue Level 
Day 1 (ng/
mg)
Tissue Level 
Day 3 (ng/
mg)
Bare 
Metal
7.11±2.91 2.90±0.99 21.16±5.60 417.3±123.5 -- --
Polymer 
Control
9.66±4.95 3.51±2.96 28.66±8.59 567.6±220.8 -- --
50 µg 7.60±4.46 3.36±2.67 22.15±10.18 447.3±230.4 0.577±0.164 0.338±0.117
150 µg 4.31±0.82* 2.39±0.49 15.98±2.39 296.6±38.3 2.32±1.12 1.48±1.54
500 µg 3.88±0.86* 1.70±0.28 15.33±3.10 281.4±49.1 5.93±1.28 4.21±0.856
1500 µg 5.44±4.02* 2.06±0.71 16.75±7.65 336.1±176.2 36.56±12.31 67.94±31.37
*= P < 
0.05; 
ANOVA/ 
Dunnetts 
Test
